Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BSX 
Boston Scientific Corp (BSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: BSX (5-star) is a REGULAR-BUY. BUY since 35 days. Simulated Profits (-1.76%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
34 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $124.53
1 Year Target Price $124.53
| 23 | Strong Buy |
| 8 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 55.44% | Avg. Invested days 66 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 155.92B USD | Price to earnings Ratio 62.11 | 1Y Target Price 124.53 |
Price to earnings Ratio 62.11 | 1Y Target Price 124.53 | ||
Volume (30-day avg) 34 | Beta 0.66 | 52 Weeks Range 80.64 - 109.50 | Updated Date 09/12/2025 |
52 Weeks Range 80.64 - 109.50 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.55% | Operating Margin (TTM) 18.63% |
Management Effectiveness
Return on Assets (TTM) 5.39% | Return on Equity (TTM) 11.55% |
Valuation
Trailing PE 62.11 | Forward PE 31.06 | Enterprise Value 166098965491 | Price to Sales(TTM) 8.43 |
Enterprise Value 166098965491 | Price to Sales(TTM) 8.43 | ||
Enterprise Value to Revenue 8.98 | Enterprise Value to EBITDA 35.75 | Shares Outstanding 1481750016 | Shares Floating 1477469372 |
Shares Outstanding 1481750016 | Shares Floating 1477469372 | ||
Percent Insiders 0.19 | Percent Institutions 93.65 |
Upturn AI SWOT
Boston Scientific Corp
Company Overview
History and Background
Boston Scientific Corp. was founded in 1979. It has grown through internal development and acquisitions to become a major medical device company.
Core Business Areas
- MedSurg: Encompasses endoscopy and urology & pelvic health, offering diagnostic and therapeutic devices and solutions to address a variety of medical conditions.
- Cardiology: Includes interventional cardiology and cardiac rhythm management, providing devices used in procedures such as angioplasty and treatment of heart rhythm disorders.
- Neuromodulation: Offers implantable devices and therapies to manage chronic pain and neurological disorders.
Leadership and Structure
The company is led by a CEO and a board of directors. The organizational structure is based on business segments and functional areas.
Top Products and Market Share
Key Offerings
- WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device: A device designed to close the left atrial appendage in patients with non-valvular atrial fibrillation to reduce the risk of stroke. Competitors include Abbott's Amulet device and Johnson & Johnson's Biosense Webster.
- POLARx Cryoablation System: A system used to treat atrial fibrillation by freezing heart tissue to disrupt abnormal electrical signals. Market competitors include Medtronic and Biosense Webster.
- Vercise Neural Navigator Deep Brain Stimulation (DBS) System: A system used for treating patients with Parkinson's disease, Essential Tremor and Dystonia. Market competitors include Medtronic and Abbott.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory oversight, and consolidation. Key trends include minimally invasive procedures, remote monitoring, and personalized medicine.
Positioning
Boston Scientific is a major player in the medical device industry with a broad portfolio of products and a strong global presence. Its competitive advantages include innovation, strong sales network, and strategic acquisitions.
Total Addressable Market (TAM)
The global medical device market is estimated to be in the hundreds of billions of dollars. Boston Scientific is well-positioned to capture a significant portion of this market due to its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Strong global presence
- Innovation capabilities
- Strategic acquisitions
- Experienced management team
Weaknesses
- Reliance on key products
- Exposure to regulatory changes
- Potential for product recalls
- Competition in key markets
Opportunities
- Expanding into emerging markets
- Developing new technologies
- Acquiring complementary businesses
- Addressing unmet medical needs
Threats
- Increased competition
- Pricing pressures
- Economic downturns
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- MDT
- ABT
- JNJ
- SYK
Competitive Landscape
Boston Scientific competes with other major medical device companies based on product innovation, pricing, and distribution. They have a competitive edge in some areas while facing challenges in others.
Major Acquisitions
Obsidio, Inc.
- Year: 2022
- Acquisition Price (USD millions): 125
- Strategic Rationale: To expand Boston Scientific's interventional oncology portfolio with a novel embolic agent.
Growth Trajectory and Initiatives
Historical Growth: Boston Scientific has experienced growth through organic sales increases and strategic acquisitions.
Future Projections: Analyst estimates for future growth would depend on factors such as product pipeline, market conditions, and economic outlook.
Recent Initiatives: Recent initiatives might include new product launches, acquisitions, partnerships, or cost-cutting measures.
Summary
Boston Scientific is a strong player in the medical device industry with a diverse portfolio and global presence. Its innovation capabilities and strategic acquisitions drive growth, but competition and regulatory changes pose challenges. The company's strong market position and commitment to innovation position it for continued success. Key areas to monitor are pricing pressures and the ability to adapt to evolving healthcare regulations. Further acquisitions will increase their total addressable market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Investor Presentations, Analyst Reports, Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data and analysis are based on publicly available information and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boston Scientific Corp
Exchange NYSE | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1992-05-18 | Chairman, President & CEO Mr. Michael F. Mahoney | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.bostonscientific.com |
Full time employees 53000 | Website https://www.bostonscientific.com | ||
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.